Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma

  • STATUS
    Recruiting
  • End date
    Mar 11, 2024
  • participants needed
    40
  • sponsor
    Cardiff Oncology
Updated on 11 March 2022

Summary

The main objective of this trial is to assess the efficacy of onvansertib in combination with nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed metastatic pancreatic ductal adenocarcinoma (PDAC).

Details
Condition Pancreatic Ductal Adenocarcinoma
Treatment fluorouracil, Leucovorin, Nanoliposomal Irinotecan, Onvansertib
Clinical Study IdentifierNCT04752696
SponsorCardiff Oncology
Last Modified on11 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically or cytologically confirmed metastatic PDAC
Has received 1 prior gemcitabine-based chemotherapy as first line therapy for metastatic disease. Progression after completion of neoadjuvant or adjuvant therapy of < 6 months in duration is considered 1 line of therapy for metastatic disease
Has measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), defined as at least 1 lesion that can be accurately measured in at least 1 dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral computed tomography (CT) scan
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
Must be willing and able to undergo a tissue biopsy at screening; participants who, in the opinion of the investigator, do not have tissue that is accessible for biopsy are excepted from this criterion
Women of childbearing potential: (defined as not post-menopausal for 12 months or no previous surgical sterilization) and fertile men must agree to use adequate contraception for the duration of study participation and for 4 months after the last dose of nal-IRI. Male subjects must agree to refrain from sperm donation during the study and for 4 months after the last dose of nal-IRI
Ability to understand and the willingness to sign a written informed consent document. Signed informed consent form must be obtained prior to initiation of study evaluations and/or activities
International Normalized Ratio (INR) < 1.5 unless on warfarin
Participants with prior malignancy and who were treated with no evidence of active disease more than 2 years from initial diagnosis are eligible
Age ≥ 18 years
Participants must have adequate organ and bone marrow function

Exclusion Criteria

Prior treatment with irinotecan, nal-IRI, or investigational PLK1 inhibitor
Uncontrolled intercurrent illness including symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, and myocardial infarction within 3 months of initiation of therapy
History of interstitial pneumonitis or interstitial lung disease
Participants with microsatellite instability-high (MSI-H) tumors with no prior immune checkpoint inhibitor exposure
Pregnancy or lactation
Participant has active and uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
QT interval with Fridericia's correction (QTcF) > 470 milliseconds. The QTcF should be calculated as the arithmetic mean of the QTcF on triplicate electrocardiograms (ECGs). In the case of potentially correctible causes of QT prolongation, (eg, medications, hypokalemia), the triplicate ECG may be repeated once during Screening and that result may be used to determine eligibility
Planned concomitant use of medications known to prolong the QT/QTc interval
Participant has undergone major surgical resection within 4 weeks prior to enrollment
Participant received radiotherapy, surgery, chemotherapy, or an investigational therapy within 2 weeks prior to study entry
Participant has serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the participant to receive an experimental research drugs
Serious psychiatric or medical conditions that could interfere with treatment
Major bleeding in the last 4 weeks
More than 1 prior chemotherapy regimen administered in the metastatic setting
Unable or unwilling to swallow oral medication
Use of strong CYP3A4 or UGT1A1 inhibitors or strong CYP3A4 inducers. Participants currently receiving these agents who are able to switch to alternate therapy are not excluded. Inhibitors should be stopped at least one week prior to the first dose of protocol therapy and inducers should be stopped at least two weeks prior to initiation of protocol therapy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note